Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...

Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

As Wegovy ushers in a new wave of weight-loss drugs to tackle India's growing obesity crisis, Dr. Rishma Pai, President-Elect ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...